| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 13
| Issue : 2 | Page : 112-119 |
|
|
Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer
Xuan Canh Nguyen1, Van Khoi Nguyen2, Minh Thong Tran3, Simone Maurea4, Marco Salvatore4
1 Unit of PET/CT and Cyclotron, Choray Hospital, Ho Chi Minh City, Vietnam
2 Center of Oncology, Choray Hospital, Ho Chi Minh City, Vietnam
3 Department of Pathology, Choray Hospital, Ho Chi Minh City, Vietnam
4 Department of Advanced Biomedical Sciences, School of Medicine and Surgery, University Federico II of Napoli, Naples, Italy
Correspondence Address:
Xuan Canh Nguyen
Unit of PET/CT and Cyclotron, Choray Hospital, 201B Nguyen Chi Thanh Street, District 5, Ho Chi Minh City
Vietnam
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1450-1147.139142
|
|
|
To assess the prognostic value of maximum standardized uptake value (maxSUV) of the primary tumor (maxSUV pt ), maxSUV of whole-body tumors (maxSUV wb ) and sum of maximum standardized uptake value (sumaxSUV) measured by the sum of maxSUVs of the primary tumor, metastatic lymph nodes, and metastatic lesions per each organ on fluoro-D-glucose-positron emission tomography/computed tomography in advanced non-small cell lung cancer (NSCLC). Eighty-three patients (49 male, 34 female) with advanced NSCLC were enrolled. Seventeen patients had Stage IIIA, 21 Stage IIIB, and 45 Stage IV. maxSUV pt , maxSUV wb , sumaxSUV, age, gender, tumor-cell type, T stage, N stage, overall stage, primary tumor size, and specific treatment were analyzed for correlation with overall survival. Median follow-up duration was 13 months. Fifty patients were dead during a median follow-up time of 11 months and 33 patients were alive with a median time of 15 months. Univariate analysis revealed that overall survival was significantly correlated with sumaxSUV (≥35 vs. <35, P = 0.004), T stage (T4 vs. T1-T3, P = 0.025), overall stage (IV vs. III, P = 0.002), gender (male vs. female, P = 0.029) and specific treatment (no vs. yes, P = 0.011). maxSUV pt and maxSUV wb were not correlated with overall survival with P value of 0.139 and 0.168, respectively. Multivariate analysis identified sumaxSUV, T stage, gender, and specific treatment as independent prognostic indicators. Patients with a sumaxSUV of ≥35 were 1.921 times more likely to die than those with a sumaxSUV of < 35 (P = 0.047). Median survival time was 14 months for patients with sumaxSUV ≥ 35 compared with 20 months for those with sumaxSUV < 35. In patients with metastatic NSCLC, sumaxSUV with cut-off of 35 was much more significant for survival prognosis (P = 0.021). sumaxSUV is a new prognostic measure, independent of tumor stage, gender, and specific treatment in advanced NSCLC. sumaxSUV may be better than maxSUV pt and maxSUV wb in prediction of survival. A large prospective cohort study is necessary to validate these results. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 471 
